The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.
An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue…
Big hospital systems are exploiting a Medicare loophole to charge older cancer patients thousands of dollars more per year for cancer treatment. Tell your members…
Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, according to new research.
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’ re speaking with…
Postintervention and 3-month follow-up assessments were evaluated to determine the feasibility and effectiveness of GET in managing distress in young Latino men with testicular cancer.
PHILADELPHIA (November 12, 2024) — For patients with cancer in the lower part of the rectum that has not spread to the lymph nodes, chemotherapy…
Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.
Sutter Medical Group (SMG) seeks to hire a BE/BC Bone Marrow Transplant Oncologist to join their dynamic team in Sacramento, CA. High income potential, (salary…
A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.
In a Science paper, Park et al. identified interleukin (IL)-1α as a key driver of positive feedback in inflammaging, linking aging-associated downregulation of DNMT3A to increased…
